The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. IGC Pharma's Revenue for the
three
months ended in Dec. 2023 was $0.20 Mil. IGC Pharma's average Accounts Receivable for the
three
months ended in Dec. 2023 was $0.11 Mil.
Hence, IGC Pharma's Receivables Turnover for the
three
months ended in Dec. 2023 was 1.78.
IGC Pharma Receivables Turnover Historical Data
The historical data trend for IGC Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IGC Pharma's Receivables Turnover
For the Biotechnology subindustry, IGC Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma's Receivables Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Receivables Turnover falls into.
IGC Pharma Receivables Turnover Calculation
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
IGC Pharma's Receivables Turnover for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
IGC Pharma Receivables Turnover Related Terms
Thank you for viewing the detailed overview of IGC Pharma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IGC has been successfully added to your 